TP53 mutations in AEL and other subtype AML patients promote the proliferation and survival of hematopoietic stem cells and progenitor cells (HSPCs), accumulating additional DNA damage, and are associated with poor prognosis [64,65]. The gene discussed is TP53; the disease is acute myeloid leukemia.